McCabe Kristin M, Booth Sarah L, Fu Xueyan, Ward Emilie, Adams Michael A, Holden Rachel M
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ont., Canada.
Am J Nephrol. 2017;45(1):4-13. doi: 10.1159/000451068. Epub 2016 Nov 16.
Patients with chronic kidney disease (CKD) have very high levels of uncarboxylated, inactive, extra-hepatic vitamin K-dependent proteins measured in circulation, putting them at risk for complications of vitamin K deficiency. The major form of vitamin K found in the liver is phylloquinone (K1). Menaquinone-4 (MK-4) is the form of vitamin K that is preferentially found in extra-hepatic tissues.
In the present study, we assessed tissue concentrations of K1 and MK-4 and the expression of vitamin K-related genes in a rat model of adenine-induced CKD.
It was found that rats with both mild and severe CKD had significantly lower amounts of K1 measured in liver, spleen and heart and higher levels of MK-4 measured in kidney cortex and medulla. All animals treated with high dietary K1 had an increase in tissue levels of both K1 and MK-4; however, the relative increase in K1 differed suggesting that the conversion of K1 to MK-4 may be a regulated/limiting process in some tissues. There was a decrease in the thoracic aorta expression of vitamin K recycling (Vkor) and utilization (Ggcx) enzymes, and a decrease in the kidney level of vitamin K1 to MK-4 bioconversion enzyme Ubiad1 in CKD.
Taken together, these findings suggest that CKD impacts vitamin K metabolism, and this occurs early in the disease course. Our findings that vitamin K metabolism is altered in the presence of CKD provides further support that sub-clinical vitamin K deficiency may represent a modifiable risk factor for vascular and bone health in this population.
慢性肾脏病(CKD)患者循环中未羧化、无活性的肝外维生素K依赖蛋白水平非常高,这使他们面临维生素K缺乏并发症的风险。肝脏中发现的维生素K的主要形式是叶绿醌(K1)。甲萘醌-4(MK-4)是在肝外组织中优先发现的维生素K形式。
在本研究中,我们评估了腺嘌呤诱导的CKD大鼠模型中K1和MK-4的组织浓度以及维生素K相关基因的表达。
发现轻度和重度CKD大鼠肝脏、脾脏和心脏中的K1含量显著降低,肾皮质和髓质中的MK-4水平升高。所有高膳食K1处理的动物组织中K1和MK-4水平均升高;然而,K1的相对升高有所不同,这表明K1向MK-4的转化在某些组织中可能是一个受调控/受限的过程。在CKD中,胸主动脉维生素K循环(Vkor)和利用(Ggcx)酶的表达降低,肾脏中维生素K1向MK-4生物转化酶Ubiad1的水平降低。
综上所述,这些发现表明CKD会影响维生素K代谢,且这种影响在疾病进程早期就会出现。我们关于CKD存在时维生素K代谢发生改变的发现进一步支持了亚临床维生素K缺乏可能是该人群血管和骨骼健康的一个可改变的风险因素。